What may help your joint? Orthobiologics Peoria answers

What can I do when it flares?

Shorten the walk or stop the reaching that made it worse. Don't spend the rest of the day in a chair, though. Easy movement can keep stiffness from taking over. For a knee, that may mean a shorter, level walk. For a shoulder, keep the arm moving where it doesn't hurt sharply. A brace helps some knees. Medicine rubbed on the skin or swallowed may ease soreness and swelling, but ask your doctor whether it fits your medical history and other pills.

Small changes won't mend a worn joint, but they may ease the next few hours.

When is it time to have someone look?

Make an appointment if the ache returns again and again, disturbs sleep, or stops you doing something that matters. Tell the doctor when it started, where you feel it, and which movement sets it off. Mention the good days as well as the bad ones. During the exam, expect the doctor to bend or turn the joint and check nearby sore spots. An X-ray may show joint wear, but it won't explain every ache.

What matters now: get the sore part named before you choose care.

What non-surgical care can I ask about?

Your doctor may talk about exercise, medicine, physical therapy, or a brace. Surgery can be right when a joint is badly worn. QC Kinetix medical providers, the people who examine you at the Peoria clinic, may offer regenerative treatments made from body material, including PRP made by drawing and spinning your blood; the first visit won't cost you. The aim may be less soreness or easier movement. It won't work for everyone.

That's the honest limit. No one can know your result before the exam.

Sources

1. The 2025 Cochrane review of stem cell injections for knee osteoarthritis pooled 25 randomised trials (1,341 participants) and found that, compared with placebo injection, stem cell injection MAY slightly improve pain (1.2 points better on a 0-10 scale, 7 studies, 445 participants) and function (14.2 points better on a 0-100 scale, 7 studies, 432 participants) up to six months - both rated LOW-certainty evidence, downgraded for indirectness (cell source, preparation and dose varied across studies) and suspected publication bias, since up to three larger RCTs were conducted and withdrawn before reporting results. Radiographic progression was not assessed in any included study.

   Whittle SL, et al. — Stem cell injections for osteoarthritis of the knee.. Cochrane Database of Systematic Reviews, 2025. DOI: 10.1002/14651858.CD013342.pub2.

2. RESTORE, the largest and most rigorously blinded placebo-controlled PRP trial in knee OA (n=288, participant-, injector- and assessor-blinded), gave three weekly injections of a commercial leukocyte-poor PRP or saline. At 12 months the change in knee pain was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and the change in medial tibial cartilage volume was -1.4% vs -1.2% (difference -0.2%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no between-group difference. The authors concluded the findings do not support the use of PRP for knee OA.

   Bennell KL, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

3. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

4. FDA states verbatim of stem cell products, stromal vascular fraction (adipose-derived cells), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products: 'None of these products have been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

5. A meta-analysis of the PLACEBO arms of 73 double-blind trials (5,895 patients) quantified what a saline knee injection alone achieves: statistically and clinically significant improvement in pain, function and quality of life at 1, 3 and 6 months, with responder rates exceeding 50% at all three time points, peaking around 4-8 months and declining by 12 months. Placebo response was stronger in trials with more female participants and in more recently published trials.

   Previtali D, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression.. EFORT Open Reviews, 2025. DOI: 10.1530/EOR-2025-0022.